The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
Serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (norepinephrine, NA) are monoamine neurotransmitters with central roles in mood regulation, cognition, autonomic function, and pain modulation. Following vesicular release into the synapse, both neurotransmitters are rapidly removed from the synaptic cleft by high-affinity, sodium-dependent reuptake transporters: SERT (serotonin transporter, encoded by SLC6A4) for 5-HT and NET (noradrenaline transporter, encoded by SLC6A2) for NA. The monoamine hypothesis of depression posits that reduced synaptic 5-HT and NA availability underlies depressive symptoms, supported by observations that drugs depleting monoamines (reserpine) can precipitate depression in susceptible individuals.
Selective serotonin reuptake inhibitors (SSRIs) competitively block SERT, increasing synaptic 5-HT concentrations across multiple brain regions including the limbic system, prefrontal cortex, and raphe nuclei. The clinical antidepressant effect requires 2-6 weeks to manifest, despite acute SERT blockade occurring within hours — indicating that chronic receptor adaptations (including 5-HT1A autoreceptor desensitisation, neurogenesis in the hippocampus, and cortical synaptic remodelling) rather than immediate neurotransmitter elevation account for therapeutic benefit. SNRIs (venlafaxine, duloxetine) inhibit both SERT and NET, with NA reuptake inhibition contributing to efficacy in neuropathic pain conditions, generalised anxiety disorder, and stress urinary incontinence.
Duloxetine's dual SERT/NET inhibition with relative 5-HT selectivity at lower doses (becoming more balanced at higher doses) has established its role across diabetic peripheral neuropathic pain, fibromyalgia, musculoskeletal pain, and stress urinary incontinence — conditions where noradrenergic pathways modulating descending pain inhibitory systems are implicated. Tricyclic antidepressants (TCAs) such as amitriptyline and nortriptyline also inhibit SERT and NET but additionally block histamine H1, muscarinic, and alpha-1 adrenergic receptors — producing anticholinergic and antihistaminergic side effects that limit their use as antidepressants but are exploited at lower doses for chronic pain, migraine prevention, and insomnia.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
Serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (norepinephrine, NA) are monoamine neurotransmitters with central roles in mood regulation, cognition, autonomic function, and pain modulation.
Following vesicular release into the synapse, both neurotransmitters are rapidly removed from the synaptic cleft by high-affinity, sodium-dependent reuptake transporters: SERT (serotonin transporter, encoded by SLC6A4) for 5-HT and NET (noradrenaline transporter, encoded by SLC6A2) for NA.
The monoamine hypothesis of depression posits that reduced synaptic 5-HT and NA availability underlies depressive symptoms, supported by observations that drugs depleting monoamines (reserpine) can precipitate depression in susceptible individuals.
Selective serotonin reuptake inhibitors (SSRIs) competitively block SERT, increasing synaptic 5-HT concentrations across multiple brain regions including the limbic system, prefrontal cortex, and raphe nuclei.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Mental Health / Psychiatry Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →